Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANL vs AURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AURA Captures Overall Composite Edge (28.8 SELL vs 48.3 HOLD), While ANL Leads 3–2 on Growth & Valuation Pillars

AURA Overall Winner 6-Pillar Tally: ANL 3 – 2 AURA (1 Tie) Matrix Metrics: ANL 4 – 4 AURA

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (28.8/100 SELL vs. 48.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while ANL wins 3–2 across the 6-pillar growth and valuation breakdown. ANL trades at $9.97 (N/M Forward P/E, -123.5% operating margin) versus AURA at $7.21 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. AURA 28.8/100 SELL), AURA captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (+0.0% vs. +178.1% YoY).
  • Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANL vs AURA
ANL US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 2.61β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $10.30 · SMA50: $12.92
AURA NASDAQ Head-to-Head Winner
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 50.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.7 · SMA20: $6.66 · SMA50: $6.54

6-Pillar Scorecard Institutional Category Breakdown (ANL 3 – 2 AURA)

Columns: Metric · ANL · AURA
1. Valuation Multiples ANL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 37.5x N/M
2. Growth & Scale ANL
Revenue Growth (YoY) +178.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $18M N/A
Market Cap $677.5M $728.6M
3. Profitability & Quality AURA
Gross Margin 100.0% N/A
Operating Margin -123.5% 0.0%
Net Profit Margin -124.8% 0.0%
Return on Equity (ROE) -20.2% -61.7%
4. Balance Sheet & Cash Flow ANL
Cash Generation (TTM) -$22M EBITDA -$110M
Cash Flow Margin -119.9% EBITDA Mgn N/A
Net Cash / Leverage $3.34 Book/Sh · -20.2% ROE $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 160.1% (22nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANL (4) vs AURA (4)
Institutional Metric ANL AURA Criterion Row Edge
Market Capitalization
Scale
$677.5M $728.6M Larger Scale AURA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+178.1% +0.0% Higher Growth ANL
Operating Margin (TTM)
Profitability
-123.5% 0.0% Higher Margin AURA
Net Profit Margin
Profitability
-124.8% 0.0% Higher Margin AURA
Return on Equity (ROE)
Capital Efficiency
-20.2% -61.7% Higher ROE ANL
52-Week Range Position
Momentum
56% ($1–$17) 52% ($5–$10) Stronger Trend ANL
Beta / 30D Volatility
Risk Regime
2.61β · 79% Vol 0.92β · 75% Vol Lower Realized Risk AURA
Unified Institutional Score
Composite Signal
48.3 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite ANL
Trailing 12M Revenue (USD)
Operating Scale
$18M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 37.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M EBITDA ($3.34 Book/Sh · -20.2% ROE) -$110M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AURA +27.81 pp
ANL: -9.61% · AURA: +18.2%
3M Horizon AURA +17.95 pp
ANL: -29.59% · AURA: -11.64%
6M Horizon AURA +10.65 pp
ANL: -14.13% · AURA: -3.48%
1Y Horizon ANL +529.88 pp
ANL: +560.26% · AURA: +30.38%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANL vs AURA. Trailing 12-month operating profitability (ANL -123.5% vs AURA 0.0%) and valuation multiples (ANL N/M vs AURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin100.0%
Op. Margin-123.5%
ROE / Fwd P/E-20.2% · N/M
AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ANL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and -123.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANL vs AURA Key Questions & Quantitative Answers

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (28.8/100 SELL vs. 48.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while ANL wins 3–2 across the 6-pillar growth and valuation breakdown. ANL trades at $9.97 (N/M Forward P/E, -123.5% operating margin) versus AURA at $7.21 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. AURA 28.8/100 SELL), AURA captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (+0.0% vs. +178.1% YoY). Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANL leads the Growth & Scale pillar: ANL posts +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin), compared with AURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANL generates $18M in USD-normalized revenue versus N/A for AURA. In operating R&D and SG&A reinvestment, ANL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AURA.

ANL screens cheaper on headline valuation multiples. ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.5x EV/Revenue (-119.9% EBITDA margin), whereas AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANL (-20.2% ROE) versus AURA (-61.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 79% Vol realized risk). By comparison, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.